Nova Eye Medical Limited (ASX: EYE) - Share Price

- Current share price for EYE : $0.135

Nova Eye Medical Limited (EYE) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack and Molteno3. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are in Fremont, California and Dunedin, New Zealand.

EYE General Information ⁺

ASX Code	EYE
Website	http://www.nova-eye.com
Industry/Sector	Health Care Equipment
Market Cap ($M)	38
EYE Share Price	$0.135
Day High	$0.140
Day Low	$0.135
Last Close	$0.135
EYE Share Price Movement	- ( No change )

Prices as at 10:00, 8 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Nova Eye Medical Limited (EYE) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
Result	13.5¢	100%	21 Jul 2020	29 Jul 2020	-	-	-

See all dividends from Nova Eye Medical Limited (EYE) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Nova Eye Medical Limited (EYE) price-sensitive announcements

EYE - Full Year Financial Results

Nova Eye Medical Limited reported a 26% increase in full-year sales to A$34.9 million for

Nova Eye Medical Limited (EYE)
26 Aug 2026 | 5:04 PM

EYE - Appendix 4E and Annual Report

The document is the Annual Report and Appendix 4E for Nova Eye Medical Limited for the fin

Nova Eye Medical Limited (EYE)
26 Aug 2026 | 4:55 PM

EYE - Quarterly Activities/Appendix 4C Cash Flow Report

Nova Eye Medical Limited reported a strong performance for the year ending 30 June 2026, a

Nova Eye Medical Limited (EYE)
29 Jul 2026 | 11:03 AM

EYE - EYE lifts Sales Guidance

Nova Eye Medical Limited has reported a record monthly sales figure in the USA for April 2

Nova Eye Medical Limited (EYE)
5 May 2026 | 9:48 AM

Nova Eye Medical Limited (EYE) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID	Health Care	$38	AGM date and closing date for Director Nominations	3 Sep 2026 4:55PM	$0.135	$0.135	fallen by 0%
Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID	Health Care	$38	Appendix 3 Y T A Spurling	28 Aug 2026 3:21PM	$0.138	$0.135	fallen by 1.82%
Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID	Health Care	$38	Appendix 4G and Corporate Governance Statement	26 Aug 2026 5:31PM	$0.143	$0.135	fallen by 5.26%
Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID	Health Care	$38	Full Year Financial Results	26 Aug 2026 5:04PM	$0.143	$0.135	fallen by 5.26%
Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID	Health Care	$38	Appendix 4E and Annual Report	26 Aug 2026 4:55PM	$0.143	$0.135	fallen by 5.26%
Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID	Health Care	$38	Notification of cessation of securities - EYE	5 Aug 2026 12:41PM	$0.140	$0.135	fallen by 3.57%

EYE Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$4.33	-$1.50	-58.50%	0.00%	0.0%
2025A	-$9.06	-$3.70	-15.10%	0.00%	0.0%
2024A	-$8.79	-$4.30	-25.30%	0.00%	0.0%

EYE Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
Cochlear Limited (COH)	$9,335M	-0.3136	0.2540	0.0785	34.7511	27.7122	25.6953	2.42%	2.51%	2.73%
Nova Eye Medical Limited (EYE)	$38M	-0.5847	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Fisher & Paykel Healthcare Corporation Limited (FPH)	$21,400M	0.1388	0.1604	0.1747	55.0129	47.4068	40.3550	1.19%	1.28%	1.45%
ResMed Inc. (RMD)	$18,734M	9.5922	0.0984	0.0885	20.5701	18.7267	17.2034	1.13%	1.23%	1.33%

EYE Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	2.69	0.00
Market	0.35	13.70	1.17	0.82
Sector	0.63	19.90	1.95	2.53

EYE Directors

Name	Position	Start Date
Mr Mike Southard	Executive Director	2 Jul 2018
Mr Victor Previn	Executive Director, Executive Chairman	16 Jul 2001
Mr Thomas (Tom) Anthony Spurling	Managing Director	29 Aug 2020
Mr Rahmon Coupe	Non-Executive Director	15 May 2013
Mr Daniel Webb	Non-Executive Director	17 Nov 2022

Nova Eye Medical Limited (EYE) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
27 Aug 2026	SPURLING, Thomas (Tom)	Buy	Direct Shares	43,493	$0.150	$6,523.950
27 Aug 2026	SPURLING, Thomas (Tom)	Buy	Direct Shares	116,507	$0.145	$16,893.515
1 Sep 2025	SPURLING, Thomas (Tom)	Buy	Direct Shares	78,273	$0.150	$11,740.950

See all changes in directors' interest & trades for Nova Eye Medical Limited (EYE) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

EYE Management

Name	Position
Simon Ramsey Alexander Gray	Company Secretary

EYE Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Nova Eye Medical Limited (EYE). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
52,624,920 (18.48%)	HSBC Custody Nominees (Australia) Limited

EYE Calendar of Events

Date	Event
25 August 2027	Report (Annual)
25 August 2027	Report (Prelim)
25 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us